Tofacitinib for Psoriatic Arthritis: What the Research Actually Shows
Tofacitinib has an unusual profile among systemic psoriasis-related treatments: it’s a cheap, widely available generic tablet in India, but it also carries one of the more serious safety warnings of any drug covered in this series. Both facts matter, and this guide covers them honestly.
What Is Tofacitinib and How Does It Work?
Tofacitinib, sold internationally as Xeljanz, is an oral Janus kinase (JAK) inhibitor. Rather than targeting a single inflammatory signal like the biologics covered elsewhere on this site, it blocks JAK enzymes that sit inside cells and relay signals from several different inflammatory cytokines at once, which broadens its effect but also broadens its side-effect profile compared to a more selective biologic.
What Tofacitinib Is Actually Approved For
This is an important distinction: tofacitinib is approved for active psoriatic arthritis (the joint-involving form of psoriatic disease), rheumatoid arthritis, and ulcerative colitis — but it is not FDA-approved specifically for plaque psoriasis of the skin. It has been studied for skin psoriasis in clinical trials, including a large Phase 3 trial (Bachelez et al., published in The Lancet) comparing it against etanercept, and an Asian-population study, with meaningful results — but its primary approved indication remains the arthritis form of the disease. If your main concern is skin plaques rather than joint symptoms, this is worth clarifying directly with your dermatologist.
A Critical Safety Warning You Should Know About
Tofacitinib carries a boxed warning — the strongest safety warning a drug can carry — based on findings from a large post-marketing safety trial (ORAL Surveillance) in rheumatoid arthritis patients over 50 with cardiovascular risk factors. That trial found increased rates of major cardiovascular events, cancer, blood clots, and death compared to TNF inhibitor biologics in this specific higher-risk population. This doesn’t mean tofacitinib is unsafe for everyone, but it does mean your doctor should specifically evaluate your cardiovascular risk factors, smoking history, and age before prescribing it, and this conversation should happen explicitly, not be assumed.
Tofacitinib Dosing
For psoriatic arthritis, the standard dose is 5 mg taken orally twice daily (or 11 mg once daily of the extended-release formulation). This is general label information — actual dosing depends on kidney function, other medications, and your specific clinical picture, and should always be confirmed with your prescribing doctor.
Tofacitinib Cost in India: A Striking Brand-vs-Generic Gap
Tofacitinib shows one of the largest brand-versus-generic price gaps of any drug in this series. Branded Xeljanz has been listed by Indian pharmaceutical suppliers at roughly ₹16,000–24,000 per bottle, while generic tofacitinib tablets manufactured domestically have been listed at as little as ₹450–555 per strip — a difference of an order of magnitude. This is only a general market reference, not a quote, and actual pricing should always be confirmed with a licensed pharmacy; but it illustrates why generic availability matters so much for a chronic condition requiring years of continuous treatment. For a broader view of how oral systemic options compare against biologics and Ayurvedic protocols on total cost, see our cost guide.
Other Side Effects to Be Aware Of
Beyond the boxed warning risks, more commonly reported side effects include upper respiratory infections, headache, diarrhea, and elevated cholesterol levels. Regular blood test monitoring — including lipid panels and blood counts — is standard practice while on tofacitinib, unlike some of the newer biologics that require less routine monitoring.
Is Tofacitinib the Right Choice for You?
Tofacitinib can be a genuinely useful, affordable oral option — particularly for psoriatic arthritis in patients without significant cardiovascular risk factors — but it’s not a drug to start without an explicit conversation about the boxed warning and appropriate monitoring. If you have a history of heart disease, smoking, blood clots, or are over 65, make sure this is discussed directly rather than assumed to be a non-issue.
This article is for general education and does not replace a consultation with a qualified rheumatologist or dermatologist. The safety information above is a summary, not a complete prescribing guide — always review full safety information with your prescribing doctor.
